Anesthesia, TIVA, Balanced Anesthesia, NK Cell

Yonsei University Health System (YUHS)

Status: Withdrawn

Conditions: Colorectal Cancer

Treatments: Drug: anesthetic method

Study type: Interventional

Funder types: Other

Identifiers

NCT05951842

3-2017-0378

Details and patient eligibility

About

Anesthetic method was reported to have an impact on postoperative long-term outcome in cancer patients. In this study, we will investigate the effect of different anesthetic methods on NK cell activity, cytokine response and postoperative outcome in colorectal cancer patients undergoing CRS and HIPEC. We will compare propofol-based total intravenous anesthesia (TIVA) with balanced anesthesia to determine the effect of propofol, inhalation agent, and opioid on tumor genesis, recurrence, NK cell activity, cytokine response, and postoperative outcome.

Sex: All

Ages: 20 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Colorectal cancer patients undergoing elective cytoreductive surgery and HIPEC (20-70 yrs old)
2. American Society of Anesthesiologists physical status I, II, III

Exclusion criteria

1. Patients under 20 years old.
2. Patients with long-term steroid therapy or immunosuppressive therapy.
3. Patients with long-term NSAIDs therapy.
4. Patients who cannot communicate with other person or with cognitive disorder.
5. Patients who cannot read the consent form.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

0 participants in 2 patient groups

TIVA group

Active Comparator group

Description:

In TIVA group, anesthesia will be maintained by propofol and remifentanil infusion under target controlled infusion. Other names: fresofol MCT 1% inj®; Fresenius kabi, Seoul, Korea, Ultian inj®; Hanlim, Seoul, Korea

Treatment:

Drug: anesthetic method

Balanced anesthesia group.

Experimental group

Description:

Anesthesia will be maintained by sevoflurane and remifentanil infusion in the balanced anesthesia group. Other names: Sojourn®, Kyongbo, Seoul, Korea, Ultian inj®; Hanlim, Seoul, Korea,

Treatment:

Drug: anesthetic method